Form 4: Vor Biopharma Director Granted Stock Options

Vor Biopharma director Andrew David Levin was granted 3,000 stock options with an exercise price of $12.80, vesting over 36 months.

Summary

• Andrew David Levin, a Director of Vor Biopharma Inc. (VOR), was granted 3,000 stock options.
• The stock options have an exercise price of $12.80 per share.
• The shares underlying the options will vest in 36 successive equal monthly installments, commencing on December 18, 2025.
• The options are set to expire on December 17, 2035.
• Levin holds these options for the benefit of RA Capital Healthcare Fund, L.P., and disclaims beneficial ownership, as he is obligated to turn over any net cash or stock received to RA Capital Management, L.P. to offset advisory fees.

Sentiment

Score: 6

Explanation: The grant of stock options is generally a positive incentive for aligning interests, but the specific arrangement where the director disclaims beneficial ownership and holds the options for an investment fund slightly reduces the direct personal incentive for the individual director.

Positives

• The grant of stock options to a director can align management's long-term interests with those of shareholders, incentivizing performance.

Negatives

• The director disclaims beneficial ownership of the options, indicating they are held on behalf of an investment fund (RA Capital), which may dilute the direct personal incentive alignment for the individual director.

Risks

• The value of the stock options is contingent on Vor Biopharma's stock price exceeding the exercise price of $12.80.
• The director's personal incentive is mitigated by the obligation to turn over proceeds to RA Capital, potentially reducing direct alignment with individual shareholder interests.

Future Outlook

The vesting schedule, extending over 36 months from December 18, 2025, implies a long-term incentive structure for the director, although the beneficial ownership disclaimer indicates an indirect personal alignment.

Management Comments

• The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on December 18, 2025, in each case subject to the Reporting Person's continued service as of each such date.
• Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Industry Context

Insider grants of stock options are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, designed to align interests with long-term company performance. The involvement of a healthcare-focused fund like RA Capital suggests a strategic investment perspective.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across many industries, including biotech, to incentivize long-term value creation.
• A 36-month vesting schedule is typical for long-term incentive plans, promoting retention and a sustained focus on performance.
• The disclaimer of beneficial ownership due to an arrangement with an investment fund (RA Capital) is a specific detail that differentiates this grant from a direct personal incentive, often seen when directors represent institutional investors.

Related Party Transactions

• The arrangement where Andrew David Levin holds options for the benefit of RA Capital Healthcare Fund, L.P., and is obligated to turn over proceeds to RA Capital Management, L.P., can be considered a related party transaction given his role as a director and potential affiliation with RA Capital.

Stakeholder Impact

• Shareholders: The grant aims to align director interests with long-term shareholder value, though indirectly due to the RA Capital arrangement.

Next Steps

• Continued service of Andrew David Levin as a director for the options to vest.
• Potential exercise of options if Vor Biopharma's stock price exceeds $12.80 before the expiration date.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction (stock option grant) for a director, with a specific arrangement involving an investment fund. It does not provide sufficient information to warrant a 'buy' or 'sell' recommendation. The grant itself is a standard incentive mechanism, but the disclaimer of beneficial ownership means it's not a direct personal investment by the director. Therefore, a 'hold' recommendation is appropriate as it does not fundamentally change the investment thesis for Vor Biopharma.

Keywords

Vor Biopharma, VOR, Stock Option, Insider Transaction, Form 4, Director Compensation, Equity Grant, RA Capital